GENFIT (GNFT.PA) Fundamental Analysis & Valuation

EPA:GNFT • FR0004163111

Current stock price

8.575 EUR
+0.08 (+1%)
Last:

This GNFT.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. GNFT.PA Profitability Analysis

1.1 Basic Checks

  • GNFT had negative earnings in the past year.
  • GNFT had a negative operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: GNFT reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: GNFT reported negative operating cash flow in multiple years.
GNFT.PA Yearly Net Income VS EBIT VS OCF VS FCFGNFT.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

1.2 Ratios

  • With a decent Return On Assets value of -17.98%, GNFT is doing good in the industry, outperforming 61.25% of the companies in the same industry.
  • With a Return On Equity value of -74.24%, GNFT perfoms like the industry average, outperforming 57.50% of the companies in the same industry.
Industry RankSector Rank
ROA -17.98%
ROE -74.24%
ROIC N/A
ROA(3y)-8.88%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GNFT.PA Yearly ROA, ROE, ROICGNFT.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

  • In the last couple of years the Profit Margin of GNFT has declined.
  • In the last couple of years the Operating Margin of GNFT has declined.
  • The Gross Margin of GNFT (95.42%) is better than 91.25% of its industry peers.
  • In the last couple of years the Gross Margin of GNFT has remained more or less at the same level.
  • GNFT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.42%
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
GNFT.PA Yearly Profit, Operating, Gross MarginsGNFT.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. GNFT.PA Health Analysis

2.1 Basic Checks

  • GNFT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for GNFT has been increased compared to 1 year ago.
  • Compared to 5 years ago, GNFT has more shares outstanding
  • GNFT has a worse debt/assets ratio than last year.
GNFT.PA Yearly Shares OutstandingGNFT.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
GNFT.PA Yearly Total Debt VS Total AssetsGNFT.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -0.62, we must say that GNFT is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of GNFT (-0.62) is worse than 61.25% of its industry peers.
  • A Debt/Equity ratio of 0.10 indicates that GNFT is not too dependend on debt financing.
  • GNFT's Debt to Equity ratio of 0.10 is fine compared to the rest of the industry. GNFT outperforms 65.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z -0.62
ROIC/WACCN/A
WACC7.62%
GNFT.PA Yearly LT Debt VS Equity VS FCFGNFT.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • GNFT has a Current Ratio of 3.74. This indicates that GNFT is financially healthy and has no problem in meeting its short term obligations.
  • GNFT's Current ratio of 3.74 is fine compared to the rest of the industry. GNFT outperforms 76.25% of its industry peers.
  • A Quick Ratio of 3.74 indicates that GNFT has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 3.74, GNFT belongs to the top of the industry, outperforming 81.25% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.74
Quick Ratio 3.74
GNFT.PA Yearly Current Assets VS Current LiabilitesGNFT.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. GNFT.PA Growth Analysis

3.1 Past

  • The earnings per share for GNFT have decreased strongly by -289.19% in the last year.
  • Measured over the past years, GNFT shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -70.77% on average per year.
  • Looking at the last year, GNFT shows a very negative growth in Revenue. The Revenue has decreased by -45.94% in the last year.
  • GNFT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.61% yearly.
EPS 1Y (TTM)-289.19%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-137.74%
Revenue 1Y (TTM)-45.94%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-43.21%

3.2 Future

  • GNFT is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -29.44% yearly.
  • The Revenue is expected to decrease by -2.23% on average over the next years.
EPS Next Y-213.72%
EPS Next 2Y-83.29%
EPS Next 3Y-41.45%
EPS Next 5Y-29.44%
Revenue Next Year-28.5%
Revenue Next 2Y-13.72%
Revenue Next 3Y-2.98%
Revenue Next 5Y-2.23%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
GNFT.PA Yearly Revenue VS EstimatesGNFT.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M
GNFT.PA Yearly EPS VS EstimatesGNFT.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. GNFT.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for GNFT. In the last year negative earnings were reported.
  • A Price/Forward Earnings ratio of 840.69 indicates a quite expensive valuation of GNFT.
  • GNFT's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. GNFT is cheaper than 70.00% of the companies in the same industry.
  • GNFT's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 24.04.
Industry RankSector Rank
PE N/A
Fwd PE 840.69
GNFT.PA Price Earnings VS Forward Price EarningsGNFT.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 200 400 600 800

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GNFT.PA Per share dataGNFT.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

  • GNFT's earnings are expected to decrease with -41.45% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-83.29%
EPS Next 3Y-41.45%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GNFT.PA Dividend Analysis

5.1 Amount

  • No dividends for GNFT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GNFT.PA Fundamentals: All Metrics, Ratios and Statistics

GENFIT

EPA:GNFT (3/16/2026, 5:27:14 PM)

8.575

+0.08 (+1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-20
Earnings (Next)04-02
Inst Owners11.39%
Inst Owner ChangeN/A
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap428.77M
Revenue(TTM)45.41M
Net Income(TTM)-38.96M
Analysts90
Price Target11.18 (30.38%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)27.15%
PT rev (3m)26.22%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)11.89%
EPS NY rev (3m)-22.74%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)9%
Revenue NY rev (3m)9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 840.69
P/S 9.44
P/FCF N/A
P/OCF N/A
P/B 8.17
P/tB 201.68
EV/EBITDA N/A
EPS(TTM)-0.7
EYN/A
EPS(NY)0.01
Fwd EY0.12%
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS0.91
BVpS1.05
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -17.98%
ROE -74.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.42%
FCFM N/A
ROA(3y)-8.88%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
F-Score2
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 188.34%
Cap/Sales 7.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.74
Quick Ratio 3.74
Altman-Z -0.62
F-Score2
WACC7.62%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-289.19%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-137.74%
EPS Next Y-213.72%
EPS Next 2Y-83.29%
EPS Next 3Y-41.45%
EPS Next 5Y-29.44%
Revenue 1Y (TTM)-45.94%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-43.21%
Revenue Next Year-28.5%
Revenue Next 2Y-13.72%
Revenue Next 3Y-2.98%
Revenue Next 5Y-2.23%
EBIT growth 1Y-217.08%
EBIT growth 3Y-53.58%
EBIT growth 5YN/A
EBIT Next Year13.75%
EBIT Next 3Y23.32%
EBIT Next 5YN/A
FCF growth 1Y87.75%
FCF growth 3Y-47.27%
FCF growth 5YN/A
OCF growth 1Y93.86%
OCF growth 3Y-46.21%
OCF growth 5YN/A

GENFIT / GNFT.PA Fundamental Analysis FAQ

What is the fundamental rating for GNFT stock?

ChartMill assigns a fundamental rating of 2 / 10 to GNFT.PA.


What is the valuation status for GNFT stock?

ChartMill assigns a valuation rating of 1 / 10 to GENFIT (GNFT.PA). This can be considered as Overvalued.


Can you provide the profitability details for GENFIT?

GENFIT (GNFT.PA) has a profitability rating of 2 / 10.


What is the expected EPS growth for GENFIT (GNFT.PA) stock?

The Earnings per Share (EPS) of GENFIT (GNFT.PA) is expected to decline by -213.72% in the next year.